These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3479047)

  • 1. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
    Drusano GL; Plaisance KI; Forrest A; Bustamante C; Devlin A; Standiford HC; Wade JC
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1420-2. PubMed ID: 3479047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
    Wade JC; Standiford HC; Drusano GL; Johnson DE; Moody MR; Bustamante CI; Joshi JH; deJongh C; Schimpff SC
    Am J Med; 1985 Jun; 78(6A):62-72. PubMed ID: 3859217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.
    Drusano GL; Forrest A; Plaisance KI; Wade JC
    Clin Pharmacol Ther; 1989 Jun; 45(6):635-41. PubMed ID: 2659235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in-vivo postantibiotic effect of imipenem and other new antimicrobials.
    Gudmundsson S; Vogelman B; Craig WA
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():67-73. PubMed ID: 3469197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
    Standiford HC; Drusano GL; Bustamante CI; Rivera G; Forrest A; Tatem B; Leslie J; Moody M
    Antimicrob Agents Chemother; 1986 Mar; 29(3):412-7. PubMed ID: 3459390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM; Leyland MJ; Kelly J; Farrell I
    J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
    Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
    Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy.
    Erjavec Z; de Vries-Hospers HG; Laseur M; Halie RM; Daenen S
    J Antimicrob Chemother; 2000 Jun; 45(6):843-9. PubMed ID: 10837439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats.
    Johnson DE; Calia FM; Snyder MJ; Warren JW; Schimpff SC
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():89-96. PubMed ID: 6583199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.
    Winston DJ; Lazarus HM; Beveridge RA; Hathorn JW; Gucalp R; Ramphal R; Chow AW; Ho WG; Horn R; Feld R; Louie TJ; Territo MC; Blumer JL; Tack KJ
    Clin Infect Dis; 2001 Feb; 32(3):381-90. PubMed ID: 11170945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
    Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
    Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
    Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
    J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):797-802. PubMed ID: 9447900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis.
    Chadwick EG; Shulman ST; Yogev R
    J Infect Dis; 1986 Oct; 154(4):670-5. PubMed ID: 3528320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem versus targeted therapy in cancer patients.
    Aoun M; Crokaert F; Paesmans M; Autier P; Klastersky J
    Int J Antimicrob Agents; 1998 Nov; 10(4):263-70. PubMed ID: 9916899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The postantibiotic effect of meropenem and imipenem on selected bacteria.
    Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
    Borja J; Herreras A
    Clin Infect Dis; 1999 Feb; 28(2):406-7. PubMed ID: 10064264
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
    Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
    J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms.
    Baquero F; Culebras E; Patrón C; Pérez-Díaz JC; Medrano JC; Vicente MF
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():47-59. PubMed ID: 3546247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.